cee
Meeting category
Date(s)
14 Oct 2021 - 15 Oct 2021
Meeting type
Virtual Meeting
CME credits
6
Organizer

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Related Enduring Materials

Enduring Materials
Preliminary Program

All times indicated in the below program are in Central European Summer Time (CEST)Click here to convert the time into your time zone.

Day 1 - Thursday, 14 October 2021
Opening of Day 1 - 14:00
14:00 CEST
Opening: Welcome, Introduction & Goals
Jürgen Rockstroh, MD
University of Bonn, Germany
Session 1: Towards Ending HIV and Viral Hepatitis: Where Do We Stand? -
Chair
Jürgen Rockstroh, MD
University of Bonn, Germany
14:05 CEST
A Report on the Progress Towards Ending HIV
Nicole Seguy, MD, MPH
WHO Regional Office for Europe, Denmark
14:20 CEST
A New Model for Monitoring Viral Hepatitis
Erika Duffell, MB, ChB
European Centre for Disease Prevention and Control (ECDC), Sweden
14:35 CEST
The Georgian Model for Hepatitis C Elimination
Tengiz Tsertsvadze, MD, PHD
Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia
14:50 CEST
EASL Guidelines on Viral Hepatitis Elimination
Mojca Matičič, MD, PhD
University of Ljubljana, Slovenia
Session 2: Hot Topics in Antiretroviral Therapy -
Chair
Pavel Khaykin, MD
MainFachArzt Frankfurt, Germany
15:35 CEST
Implementation of Integrase Inhibitors for First Line Therapy in the CEE Region: How Far Are We?
Miłosz Parczewski, MD, PhD
Pomeranian Medical University, Szczecin, Poland
15:50 CEST
Update on the Use of Generic Drugs for HIV in Europe
Mila Maistat
Medicines Patent Pool (MPP), Switzerland
16:05 CEST
HIV in Women: What Is New?
Annette Haberl, MD 
Hospital of the Johann Wolfgang Goethe-University Frankfurt, Germany
Guided Poster Tour -
Chair
David Jilich, MD, Ph.D
Hospital Na Bulovce, Czech Republic
16:50 CEST
Evaluate Potential Impact of COVID-19 Pandemic on HIV Testing and Care National Program in the Republic of Georgia (#5)
Dr. Otar Chokoshvili
Infectious Diseases, Aids And Clinical Immunology Research Center, Georgia
16:53 CEST
Effect of Remdesivir on Mortality in Patients with COVID-19: A Retrospective Cohort Study (#6)
Mr. Revaz Metchurtchlishvili
Infectious Diseases, Aids And Clinical Immunology Research Center, Georgia
16:56 CEST
Integrating Viral Hepatitis and PrEP Services Through KP-Led Clinics in Vietnam: An Opportunity to Achieve Dual Elimination of HIV and Viral Hepatitis by 2030 (#7)
Dr. Bao Vu
PATH, Vietnam
16:59 CEST
Prevalence of Undiagnosed HBV Infection in Patients with COVID-19 (#8)
Dr. Victor Daniel Miron
Carol Davila Univ Med Pharm, Natl Inst Infect Dis Prof Dr Matei Bals, Romania
Poster Viewing Session - 17:20
17:20 CEST
Poster Presentations
Day 2 - Friday, 15 October 2021
Session 3: What Is New in Prevention? -
Chair
Adrian Streinu–Cercel, MD, PhD
National Institute of Infectious Diseases "Prof. Dr. Matei Bals", Romania
14:05 CEST
Update on Guidelines for Preventing Vertical Transmission of HEP B
14:20 CEST
Rollout of PrEP in Europe: Success Stories and Challenges
Teymur Noori, MSc
European Centre for Disease Prevention and Control (ECDC), Sweden
14:35 CEST
Long-Acting Therapy for PrEP: How Will We Use it?
Luis Mendão
European AIDS Treatment Group, Belgium
14:50 CEST
HIV Prevention in High Risk Populations: Unique Challenges and Solutions
Jean-Michel Molina, MD, PhD
Saint-Louis/Lariboisière Hospitals and University of Paris, France
Session 4: Abstract-Driven Presentations -
Chair
Nikoloz Chkhartishvili, MD, MS, PhD
Infectious Diseases, AIDS and Clinical Immunology Research Center, Georgia
15:35 CEST
Rate of HCV Reinfection Among People Living with HCV Following Successful DAA Therapy in Tbilisi, Georgia (#1)
Prof. Lali Sharvadze
Infectious Diseases, Aids And Clinical Immunology Research Center, Georgia
15:40 CEST
SARS-CoV-2 Antibody Seroprevalence in Previously Undiagnosed Persons in Tbilisi, Georgia: Results of Three Repeated Serosurveys (#2)
Dr. Akaki Abutidze
Infectious Diseases, Aids And Clinical Immunology Research Center, Georgia
15:45 CEST
COVID-19 Challenges and Scale-up in Access to Community-Based HCV Treatment for HIV/HCV Co-infected PWIDs in Ukraine (#3)
Mr. Zahedul Islam
Alliance for Public Health, Ukraine
15:50 CEST
Dynamics and Peculiarities of AIDS Mortality in Minsk, Belarus (#4)
Mrs. Marharyta Shylava
Belarusian State Medical University, Belarus
Session 5: HIV or Viral Hepatitis & COVID Coinfection -
Chair
Jürgen Rockstroh, MD
University of Bonn, Germany
16:25 CEST
Update on COVID-19 Therapeutics
Daniel Kuritzkes, MD
Brigham and Women's Hospital / Harvard Medical School, United States
16:40 CEST
SARS-COV-2 Vaccines: A Critical Review
Kathryn Stephenson, MD, MPH
Harvard Medical School / Ragon Institute / Beth Israel Deaconess Medical Center, United States
16:55 CEST
Liver Disease and COVID-19 Coinfection
Cihan Yurdaydin, MD
Department of Gastroenterology and Hepatology, University Medical School, Istanbul, Turkey
17:10 CEST
HIV & COVID-19 Coinfection
Anca Streinu-Cercel, MD, PhD
National Institute of Infectious Diseases "Prof. Dr. Matei Bals", Romania
17:25 CEST
Discussion
17:40 CEST
Closing Remarks
Jürgen Rockstroh, MD
University of Bonn, Germany
Language
Sorry… This form is closed to new submissions.